Summarizing, on the basis of our data, it is possible to suggest that the p53 inhibitor and activator of specific S1P receptor(s) and Sirts should be considered for cytoprotection and, in consequence, for the improvement of the AD therapeutic strategy. This evidence concerns the gene TP53 and Alzheimer disease.